AngioDynamics提交10-K年報 市值約4.36億美元 聚焦NanoKnife等醫療技術

ango-202605310001275187false2026FYP2YP2YP4YP3Yhttp://fasb.org/us-gaap/2026#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2026#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2026#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2026#OtherLiabilitiesNoncurrenthttp://www.angiodynamics.com/20260531#AcquisitionRestructuringAndOtherItemsNethttp://www.angiodynamics.com/20260531#AcquisitionRestructuringAndOtherItemsNetiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesango:reporting_unitango:asset_groupango:revenue_streamxbrli:pureango:voteango:periodango:working_hourango:patentango:paymentango:claimango:segment00012751872025-06-012026-05-3100012751872025-11-3000012751872026-07-1000012751872026-03-012026-05-3100012751872024-06-012025-05-3100012751872023-06-012024-05-310001275187us-gaap:RetainedEarningsMember2025-06-012026-05-3100012751872026-05-3100012751872025-05-310001275187us-gaap:CommonStockMember2023-05-310001275187us-gaap:AdditionalPaidInCapitalMember2023-05-310001275187us-gaap:RetainedEarningsMember2023-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-05-310001275187us-gaap:TreasuryStockCommonMember2023-05-3100012751872023-05-310001275187us-gaap:RetainedEarningsMember2023-06-012024-05-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2023-06-012024-05-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2023-06-012024-05-310001275187us-gaap:RestrictedStockUnitsRSUMember2023-06-012024-05-310001275187us-gaap:PerformanceSharesMemberus-gaap:CommonStockMember2023-06-012024-05-310001275187us-gaap:PerformanceSharesMemberus-gaap:AdditionalPaidInCapitalMember2023-06-012024-05-310001275187us-gaap:PerformanceSharesMember2023-06-012024-05-310001275187us-gaap:CommonStockMember2023-06-012024-05-310001275187us-gaap:AdditionalPaidInCapitalMember2023-06-012024-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-012024-05-310001275187us-gaap:CommonStockMember2024-05-310001275187us-gaap:AdditionalPaidInCapitalMember2024-05-310001275187us-gaap:RetainedEarningsMember2024-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-05-310001275187us-gaap:TreasuryStockCommonMember2024-05-3100012751872024-05-310001275187us-gaap:RetainedEarningsMember2024-06-012025-05-310001275187us-gaap:CommonStockMember2024-06-012025-05-310001275187us-gaap:AdditionalPaidInCapitalMember2024-06-012025-05-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2024-06-012025-05-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2024-06-012025-05-310001275187us-gaap:RestrictedStockUnitsRSUMember2024-06-012025-05-310001275187us-gaap:TreasuryStockCommonMember2024-06-012025-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-012025-05-310001275187us-gaap:CommonStockMember2025-05-310001275187us-gaap:AdditionalPaidInCapitalMember2025-05-310001275187us-gaap:RetainedEarningsMember2025-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-05-310001275187us-gaap:TreasuryStockCommonMember2025-05-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2025-06-012026-05-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2025-06-012026-05-310001275187us-gaap:RestrictedStockUnitsRSUMember2025-06-012026-05-310001275187us-gaap:CommonStockMember2025-06-012026-05-310001275187us-gaap:AdditionalPaidInCapitalMember2025-06-012026-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-012026-05-310001275187us-gaap:CommonStockMember2026-05-310001275187us-gaap:AdditionalPaidInCapitalMember2026-05-310001275187us-gaap:RetainedEarningsMember2026-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-05-310001275187us-gaap:TreasuryStockCommonMember2026-05-310001275187srt:MinimumMember2025-06-012026-05-310001275187srt:MaximumMember2025-06-012026-05-310001275187us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2026-05-310001275187us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2026-05-310001275187us-gaap:ComputerEquipmentMembersrt:MinimumMember2026-05-310001275187us-gaap:ComputerEquipmentMembersrt:MaximumMember2026-05-310001275187us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2026-05-310001275187us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2026-05-310001275187ango:PlacementAndEvaluationUnitsMember2026-05-310001275187srt:MinimumMember2026-05-310001275187srt:MaximumMember2026-05-310001275187us-gaap:EmployeeStockOptionMember2025-06-012026-05-310001275187us-gaap:RestrictedStockMember2025-06-012026-05-310001275187us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberango:PICCAndMidlineBusinessesMember2024-02-290001275187us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberango:PICCAndMidlineBusinessesMember2024-12-012025-02-280001275187us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberango:PICCAndMidlineBusinessesMember2025-03-012025-05-310001275187us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberango:PICCAndMidlineBusinessesMember2024-02-150001275187us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberango:DialysisAndBioSentryTractSealantSystemBiopsyBusinessesMember2023-06-080001275187us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberango:DialysisAndBioSentryTractSealantSystemBiopsyBusinessesMember2023-06-082023-06-080001275187country:USango:MedTechSegmentMember2025-06-012026-05-310001275187us-gaap:NonUsMemberango:MedTechSegmentMember2025-06-012026-05-310001275187ango:MedTechSegmentMember2025-06-012026-05-310001275187country:USango:MedTechSegmentMember2024-06-012025-05-310001275187us-gaap:NonUsMemberango:MedTechSegmentMember2024-06-012025-05-310001275187ango:MedTechSegmentMember2024-06-012025-05-310001275187country:USango:MedDeviceSegmentMember2025-06-012026-05-310001275187us-gaap:NonUsMemberango:MedDeviceSegmentMember2025-06-012026-05-310001275187ango:MedDeviceSegmentMember2025-06-012026-05-310001275187country:USango:MedDeviceSegmentMember2024-06-012025-05-310001275187us-gaap:NonUsMemberango:MedDeviceSegmentMember2024-06-012025-05-310001275187ango:MedDeviceSegmentMember2024-06-012025-05-310001275187country:US2025-06-012026-05-310001275187us-gaap:NonUsMember2025-06-012026-05-310001275187country:US2024-06-012025-05-310001275187us-gaap:NonUsMember2024-06-012025-05-310001275187country:USango:MedTechSegmentMember2023-06-012024-05-310001275187us-gaap:NonUsMemberango:MedTechSegmentMember2023-06-012024-05-310001275187ango:MedTechSegmentMember2023-06-012024-05-310001275187country:USango:MedDeviceSegmentMember2023-06-012024-05-310001275187us-gaap:NonUsMemberango:MedDeviceSegmentMember2023-06-012024-05-310001275187ango:MedDeviceSegmentMember2023-06-012024-05-310001275187country:US2023-06-012024-05-310001275187us-gaap:NonUsMember2023-06-012024-05-310001275187us-gaap:BuildingAndBuildingImprovementsMember2026-05-310001275187us-gaap:BuildingAndBuildingImprovementsMember2025-05-310001275187us-gaap:ComputerEquipmentMember2026-05-310001275187us-gaap:ComputerEquipmentMember2025-05-310001275187us-gaap:MachineryAndEquipmentMember2026-05-310001275187us-gaap:MachineryAndEquipmentMember2025-05-310001275187ango:PlacementAndEvaluationUnitsMember2025-05-310001275187us-gaap:ConstructionInProgressMember2026-05-310001275187us-gaap:ConstructionInProgressMember2025-05-310001275187ango:PropertyPlantAndEquipmentExcludingLandAndImprovementsMember2026-05-310001275187ango:PropertyPlantAndEquipmentExcludingLandAndImprovementsMember2025-05-310001275187ango:PropertyPlantAndEquipmentExcludingBuildingMember2026-05-310001275187ango:PropertyPlantAndEquipmentExcludingBuildingMember2025-05-310001275187ango:LandAndAndImprovementsMember2026-05-310001275187ango:LandAndAndImprovementsMember2025-05-310001275187ango:ProductTechnologiesMember2026-05-310001275187us-gaap:CustomerRelationshipsMember2026-05-310001275187us-gaap:TrademarksMember2026-05-310001275187us-gaap:LicenseAgreementTermsMember2026-05-310001275187ango:ProductTechnologiesMember2025-05-310001275187us-gaap:CustomerRelationshipsMember2025-05-310001275187us-gaap:TrademarksMember2025-05-310001275187us-gaap:LicenseAgreementTermsMember2025-05-310001275187ango:EximoMedicalLtd.Member2026-05-310001275187ango:EximoMedicalLtd.Member2025-05-310001275187us-gaap:DomesticCountryMember2026-05-310001275187us-gaap:DomesticCountryMemberango:TaxPeriodOneMember2026-05-310001275187us-gaap:DomesticCountryMemberango:TaxPeriodFourMember2026-05-310001275187us-gaap:StateAndLocalJurisdictionMemberango:TaxPeriodThreeMember2026-05-310001275187us-gaap:IsraelTaxAuthorityMemberango:TaxPeriodFourMember2026-05-310001275187stpr:TX2025-06-012026-05-310001275187us-gaap:StateAndLocalTaxJurisdictionOtherMember2025-06-012026-05-310001275187country:CA2025-06-012026-05-310001275187country:FR2025-06-012026-05-310001275187country:NL2025-06-012026-05-310001275187country:GB2025-06-012026-05-310001275187us-gaap:ForeignTaxJurisdictionOtherMember2025-06-012026-05-310001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2025-05-280001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2025-05-282025-05-280001275187us-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2025-05-280001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2025-05-282025-05-280001275187us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2025-05-282025-05-280001275187us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMember2025-05-282025-05-280001275187us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberus-gaap:BaseRateMember2025-05-282025-05-2800012751872014-10-2900012751872014-10-292014-10-290001275187ango:EmployeeStockPurchasePlanMember2022-11-032022-11-030001275187ango:EmployeeStockPurchasePlanMember2023-11-142023-11-140001275187ango:A2020StockAndIncentiveAwardPlanMember2024-11-122024-11-120001275187ango:TwoThousandAndFourStockAndIncentiveAwardPlanMember2026-05-310001275187us-gaap:EmployeeStockOptionMember2023-06-012024-05-310001275187us-gaap:EmployeeStockOptionMember2024-06-012025-05-310001275187us-gaap:RestrictedStockUnitsRSUMember2025-05-310001275187us-gaap:RestrictedStockUnitsRSUMember2026-05-310001275187ango:PerformanceShareAndRestrictedStockUnitAwardsMember2025-06-012026-05-310001275187ango:PerformanceShareAndRestrictedStockUnitAwardsMember2024-06-012025-05-310001275187ango:PerformanceShareAndRestrictedStockUnitAwardsMember2023-06-012024-05-310001275187us-gaap:PerformanceSharesMember2025-05-310001275187us-gaap:PerformanceSharesMember2025-06-012026-05-310001275187us-gaap:PerformanceSharesMember2026-05-310001275187ango:PerformanceSharesIncludingThreeYearMarketConditionMember2025-06-012026-05-310001275187ango:PerformanceSharesIncludingThreeYearMarketConditionMember2026-05-310001275187ango:PerformanceSharesIncludingThreeYearMarketConditionMember2025-05-310001275187ango:PerformanceSharesIncludingThreeYearMarketConditionMember2024-05-310001275187us-gaap:CostOfGoodsAndServicesSold2025-06-012026-05-310001275187us-gaap:CostOfGoodsAndServicesSold2024-06-012025-05-310001275187us-gaap:CostOfGoodsAndServicesSold2023-06-012024-05-310001275187us-gaap:ResearchAndDevelopmentExpense2025-06-012026-05-310001275187us-gaap:ResearchAndDevelopmentExpense2024-06-012025-05-310001275187us-gaap:ResearchAndDevelopmentExpense2023-06-012024-05-310001275187us-gaap:SellingAndMarketingExpense2025-06-012026-05-310001275187us-gaap:SellingAndMarketingExpense2024-06-012025-05-310001275187us-gaap:SellingAndMarketingExpense2023-06-012024-05-310001275187us-gaap:GeneralAndAdministrativeExpense2025-06-012026-05-310001275187us-gaap:GeneralAndAdministrativeExpense2024-06-012025-05-310001275187us-gaap:GeneralAndAdministrativeExpense2023-06-012024-05-310001275187ango:AcquisitionRestructuringAndOtherItemsNet2025-06-012026-05-310001275187ango:AcquisitionRestructuringAndOtherItemsNet2024-06-012025-05-310001275187ango:AcquisitionRestructuringAndOtherItemsNet2023-06-012024-05-310001275187ango:StockPurchasePlanMember2026-05-310001275187ango:StockPurchasePlanMember2025-06-012026-05-310001275187ango:StockPurchasePlanMember2024-06-012025-05-310001275187ango:StockPurchasePlanMember2023-06-012024-05-310001275187ango:RepurchaseProgramJuly2024Member2024-07-160001275187ango:RepurchaseProgramJuly2024Member2025-06-012026-05-310001275187ango:RepurchaseProgramJuly2024Member2024-06-012025-05-310001275187ango:RepurchaseProgramJuly2024Member2026-05-310001275187ango:ManufacturingFacilitiesInQueensburyNYMember2024-12-242024-12-240001275187ango:ManufacturingFacilitiesInGlensFallsNYMember2024-12-242024-12-240001275187ango:ManufacturingFacilitiesInQueensburyNYMember2024-12-240001275187ango:ManufacturingFacilitiesInGlensFallsNYMember2024-12-240001275187ango:CrBardIncMember2012-01-112012-01-110001275187ango:BectonDickinsonAndCompanyC.R.BardInc.AndBardPeripheralVascularInc.Member2024-03-312024-03-310001275187ango:BectonDickinsonAndCompanyC.R.BardInc.AndBardPeripheralVascularInc.Member2024-04-012024-04-050001275187ango:BectonDickinsonAndCompanyC.R.BardInc.AndBardPeripheralVascularInc.Member2025-06-012026-05-310001275187ango:BectonDickinsonAndCompanyC.R.BardInc.AndBardPeripheralVascularInc.Member2026-05-310001275187ango:PortsProductClaimsMember2026-05-310001275187ango:MedTechSegmentMember2025-06-012026-05-310001275187ango:MedTechSegmentMember2024-06-012025-05-310001275187ango:MedTechSegmentMember2023-06-012024-05-310001275187ango:MedDeviceSegmentMember2025-06-012026-05-310001275187ango:MedDeviceSegmentMember2024-06-012025-05-310001275187ango:MedDeviceSegmentMember2023-06-012024-05-310001275187us-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-06-012026-05-310001275187us-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-06-012025-05-310001275187us-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-06-012024-05-310001275187country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:NetAssetsGeographicAreaMember2025-06-012026-05-310001275187country:ILus-gaap:GeographicConcentrationRiskMemberus-gaap:NetAssetsGeographicAreaMember2025-06-012026-05-310001275187ango:LegalCostsMember2025-06-012026-05-310001275187ango:LegalCostsMember2024-06-012025-05-310001275187ango:LegalCostsMember2023-06-012024-05-310001275187ango:MergersandAcquisitionsMember2025-06-012026-05-310001275187ango:MergersandAcquisitionsMember2024-06-012025-05-310001275187ango:MergersandAcquisitionsMember2023-06-012024-05-310001275187ango:TransitionServiceAgreementMember2025-06-012026-05-310001275187ango:TransitionServiceAgreementMember2024-06-012025-05-310001275187ango:TransitionServiceAgreementMember2023-06-012024-05-310001275187us-gaap:FacilityClosingMember2025-06-012026-05-310001275187us-gaap:FacilityClosingMember2024-06-012025-05-310001275187us-gaap:FacilityClosingMember2023-06-012024-05-310001275187ango:ManufacturingRelocationMember2025-06-012026-05-310001275187ango:ManufacturingRelocationMember2024-06-012025-05-310001275187ango:ManufacturingRelocationMember2023-06-012024-05-3100012751872023-12-012024-02-290001275187ango:IntangibleImpairmentMember2025-06-012026-05-310001275187ango:IntangibleImpairmentMember2024-06-012025-05-310001275187ango:IntangibleImpairmentMember2023-06-012024-05-310001275187ango:IsraeliInnovationAuthorityPrepaymentMember2025-06-012026-05-310001275187ango:IsraeliInnovationAuthorityPrepaymentMember2024-06-012025-05-310001275187ango:IsraeliInnovationAuthorityPrepaymentMember2023-06-012024-05-310001275187us-gaap:OtherRestructuringMember2025-06-012026-05-310001275187us-gaap:OtherRestructuringMember2024-06-012025-05-310001275187us-gaap:OtherRestructuringMember2023-06-012024-05-310001275187ango:BectonDickinsonAndCompanyC.R.BardInc.AndBardPeripheralVascularInc.Memberango:LegalCostsMember2025-12-012026-02-280001275187srt:MinimumMemberus-gaap:FacilityClosingMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberus-gaap:FacilityClosingMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MinimumMemberus-gaap:OneTimeTerminationBenefitsMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberus-gaap:OneTimeTerminationBenefitsMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MinimumMemberango:OutsideConsultantsMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberango:OutsideConsultantsMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MinimumMemberango:ValidationExpensesMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberango:ValidationExpensesMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MinimumMemberango:RegulatoryFilingsMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberango:RegulatoryFilingsMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MinimumMemberus-gaap:OtherRestructuringMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberus-gaap:OtherRestructuringMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187ango:ManufacturingShiftToOutsourcedModelModifiedMembersrt:MinimumMember2026-05-310001275187ango:ManufacturingShiftToOutsourcedModelModifiedMembersrt:MaximumMember2026-05-310001275187srt:MinimumMemberango:FacilityClosingAcceleratedDepreciationAndImpairmentMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187srt:MaximumMemberango:FacilityClosingAcceleratedDepreciationAndImpairmentMemberango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187ango:ManufacturingShiftToOutsourcedModelModifiedMember2025-06-012026-05-310001275187ango:ManufacturingShiftToOutsourcedModelModifiedMember2024-06-012025-05-310001275187ango:ManufacturingShiftToOutsourcedModelModifiedMember2023-06-012024-05-310001275187ango:ManufacturingShiftToOutsourcedModelModifiedMember2026-05-310001275187us-gaap:OneTimeTerminationBenefitsMember2025-05-310001275187ango:OutsideConsultantsMember2025-05-310001275187ango:ValidationExpensesMember2025-05-310001275187us-gaap:FacilityClosingMember2025-05-310001275187ango:RegulatoryFilingsMember2025-05-310001275187us-gaap:OtherRestructuringMember2025-05-310001275187us-gaap:OneTimeTerminationBenefitsMember2025-06-012026-05-310001275187ango:OutsideConsultantsMember2025-06-012026-05-310001275187ango:ValidationExpensesMember2025-06-012026-05-310001275187ango:RegulatoryFilingsMember2025-06-012026-05-310001275187us-gaap:OneTimeTerminationBenefitsMember2026-05-310001275187ango:OutsideConsultantsMember2026-05-310001275187ango:ValidationExpensesMember2026-05-310001275187us-gaap:FacilityClosingMember2026-05-310001275187ango:RegulatoryFilingsMember2026-05-310001275187us-gaap:OtherRestructuringMember2026-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-06-012024-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2023-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2023-06-012024-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2024-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-06-012025-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2025-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2024-06-012025-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2025-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2025-06-012026-05-310001275187us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2026-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2025-06-012026-05-310001275187ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember2026-05-31

 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended May 31, 2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                  

Commission file number 0-50761

AngioDynamics, Inc.
(Exact name of registrant as specified in its charter)

Delaware 11-3146460
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)

14 Plaza Drive, Latham, New York 12110 
(Address of principal executive offices and zip code)
(518) 795-1400 
Registrant’s telephone number, including area code
 

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $.01 per shareANGONASDAQ Global Select Market
 

Securities registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒   No  ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer☐  Accelerated filer☒
Non-accelerated filer☐  Smaller reporting company☐
Emerging growth company☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  Yes  ☒    No  ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of November 30, 2025, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates was approximately $436,293,219 computed by reference to the last sale price of the common stock on that date as reported by The NASDAQ Global Select Market.

As of July 10, 2026 there were 41,332,389 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
The information required for Part III of this Annual Report on Form 10-K is incorporated by reference to the registrant’s Proxy Statement for its 2026 Annual Meeting of Stockholders to be filed within 120 days of the registrant's fiscal year ended May 31, 2026. 

AngioDynamics, Inc. and Subsidiaries
INDEX
 

Page
Part I:
Item 1.Business
2

Item 1A.Risk Factors
15

Item 1B.Unresolved Staff Comments
30

Item 1C.Cyber Security
30

Item 2.Properties
30

Item 3.Legal Proceedings
31

Item 4.Mine Safety Disclosures
31

Part II:
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
32

Item 6.[Reserved]
33

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations
33

Item 7A.Quantitative and Qualitative Disclosures About Market Risk
43

Item 8.Financial Statements and Supplementary Data
43

Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
43

Item 9A.Controls and Procedures
44

Item 9B.Other Information
46

Item 9C.Foreign Jurisdictions that Prevent Inspections
46

Part III:
Item 10.Directors, Executive Officers and Corporate Governance
47

Item 11.Executive Compensation
47

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
47

Item 13.Certain Relationships and Related Transactions, and Director Independence
47

Item 14.Principal Accounting Fees and Services
47

Part IV:
Item 15.Exhibits, Financial Statement Schedules
48

1

Part I
Unless otherwise indicated in this report, "AngioDynamics," the "Company," "we," "our" or "us" refers to AngioDynamics, Inc and our consolidated subsidiaries. 
Disclosure Regarding Forward-Looking Statements
This annual report on Form 10-K, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC").
Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this annual report on Form 10-K will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Disclosure Regarding Trademarks
This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames. For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP.

Item 1. Business.
OVERVIEW
AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance.
HISTORY
AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility. Initially dedicated to the research and development of products used in interventional radiology, the Company soon became well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.
2

The Company grew over the following years as a result of acquisitions of companies including RITA Medical Systems in January 2007, Oncobionic in May 2008, the assets of Diomed in June 2008, Vortex Medical, Inc. in October 2012, the assets of Microsulis Medical Limited in January 2013, and Clinical Devices in August 2013. These acquisitions added product lines including ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization products and venous products. In May 2012, the Company acquired Navilyst Medical's Fluid Management business, which the Company sold in May 2019 to Medline Industries, Inc. pursuant to an asset purchase agreement. 
In August 2018, the Company acquired the BioSentry product line from Surgical Specialties, LLC, which the Company sold in June 2023 to Merit Medical Systems, Inc. pursuant to an asset purchase agreement. In September 2018, the Company acquired RadiaDyne, which included endorectal and vaginal balloons. On October 2, 2019, the Company acquired Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm laser atherectomy technology (now called Auryon), which treats Peripheral Artery Disease. On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc. On July 27, 2021, AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC. 
On June 8, 2023, the Company completed the sale of the dialysis and BioSentry businesses to Merit Medical Systems, Inc. On February 15, 2024, the Company completed the sale of its PICC and Midline businesses, which included the C3 Wave tip location asset, to Spectrum Vascular. As of February 29, 2024, the Company discontinued the RadioFrequency Ablation and Syntrax product lines.
AngioDynamics is publicly traded on the NASDAQ stock exchange under the symbol ANGO.
PRODUCTS
Our product offerings fall within two segments, Med Tech and Med Device. All products discussed below have been cleared for sale in the United States by the Food and Drug Administration. International regulatory clearances vary by product and jurisdiction.
Med Tech 
Auryon 
The Auryon Atherectomy System represents one of our latest advancements in the treatment of peripheral arterial disease. The device is engineered to deliver an optimized wavelength and short pulse width to remove a wide range of lesion types while minimizing damage to the vessel wall endothelium. Incorporating integrated aspiration, the Auryon System enhances procedural safety by helping remove plaque from the vasculature. The device delivers safe, effective and versatile treatment across a broad spectrum of lesion types and anatomical locations including above and below the knee. Designed for flexibility, the device supports femoral, pedal or radial access allowing physicians to expand treatment options for their patients. The Auryon system delivers a safe, efficient and comprehensive treatment option on one single platform.

Thrombectomy
Our Thrombus Management portfolio includes the AlphaVac Mechanical Thrombectomy System, AngioVac venous drainage cannula and circuit, as well as catheter directed thrombolytic devices, including the Uni-Fuse system and the Uni-Fuse+ system. AngioDynamics offers a range of options when treating thrombus and removing fresh, soft thrombi or emboli.

3

AngioVac

Our AngioVac venous drainage system includes a Venous Drainage Cannula and Extracorporeal Circuit. The cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass. The AngioVac circuit is indicated for use in procedures requiring extracorporeal circulatory support for periods of up to six hours. AngioVac devices are for use with other manufacturers’ off-the-shelf pump, filter and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. 

The AngioVac venous drainage cannula is a 22 French flat coil-reinforced cannula designed with a proprietary self-expanding nitinol reinforced funnel shaped distal tip. The funnel shaped tip enhances venous drainage flow when the distal tip is exposed by retracting the sheath, helps prevent clogging of the cannula with commonly encountered undesirable intravascular material, and facilitates embolic removal of such extraneous material.
AlphaVac 

The AlphaVac System is an emergent mechanical aspiration device that eliminates the need for perfusionist support. AlphaVac is offered in both a 22 French flat coil-reinforced cannula and an 18 French braided reinforced cannula each designed with a proprietary self-expanding nitinol reinforced funnel shaped distal tip. AlphaVac is indicated for the non-surgical removal of thrombi or emboli from vasculature as well as aspiration of contrast media and other fluids from the vasculature. The cannula is intended for use in the venous system. The handle is indicated as a vacuum source for the AlphaVac MMA system. The AlphaVac F18 system is indicated for the treatment of pulmonary embolism and allows for the utilization in the non-surgical removal of thrombi or emboli from the venous vasculature, reducing thrombus burden and improving right ventricular function in patients with PE.

 

 

Thrombolytic Catheters
Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. AngioDynamics’ Uni-Fuse infusion catheter features pressure response outlets, a proprietary slit technology that provides a consistent, even distribution of fluid volume along the entire length of the infusion pattern, designed to provide an advantage over standard side-hole catheters.

4

NanoKnife

The NanoKnife IRE Ablation System is an alternative to traditional thermal ablation that received 510(k) clearance from the Food and Drug Administration for the surgical ablation of soft tissue. The system utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. These permanent pores or nano-scale defects in the cell membranes result in cell death. The treated tissue is then removed by the body’s natural processes in a matter of weeks, mimicking natural cell death. Unlike other ablation technologies, the NanoKnife System does not achieve tissue ablation using thermal energy.
 

The NanoKnife System consists of two major components: a Low Energy Direct Current, or LEDC Generator and needle-like electrode probes. Up to six (6) electrode probes can be placed into or around the targeted soft tissue. Once the probes are in place, the user enters the appropriate parameters for voltage, number of pulses, interval between pulses, and the pulse length into the generator user interface. The generator then delivers a series of short electric pulses between each electrode probe. Full paralytic anesthesiology is required for safe IRE delivery.
In December 2024, the NanoKnife System received expanded FDA 510(k) clearance for the ablation of prostate tissue which broadens treatment options for men and reinforces the system’s strong safety and efficacy profile. 
In February 2026, the NanoKnife system received BSI approval for the product to bear the MDR CE mark supporting expanded indications for the ablation of pancreas, kidney, liver or prostate tumors, including intermediate risk prostate cancer. 

Med Device
Peripheral Products (Interventional Devices)
We offer a comprehensive portfolio of products for use during minimally invasive procedures. Product categories include an extensive line of angiographic catheters, guidewires, drainage catheters and micropuncture kits.
Angiographic Catheters & Guidewires
Our extensive line of various angiographic catheter configurations are designed to allow physicians to navigate and reach targeted anatomical locations within a patient’s vasculature that are in need of angiographic diagnosis. Typically run over a diagnostic guidewire, our angiographic catheters allow physicians to deliver contrast media to the desired location to determine the diagnosis and subsequent therapeutic modalities, as needed for the patient. 
AngioDynamics offers three different angiographic catheter lines to meet physicians’ procedural needs. All of our catheters feature our soft, atraumatic, super-radiopaque tip that is uniquely welded to our co-extruded nylon shaft, which provides excellent visibility under fluoroscopy and re-enforced tip stability.
•Soft-Vu Angiographic Catheters highlight the soft, atraumatic super-radiopaque and proprietary tip-to-shaft weld in a full offering of different tip shapes, lengths and French sized flush and selective catheters. Flush catheters are used in procedures where a large volume of contrast is required to deliver a concentrated bolus of contrast quickly for visualization or larger anatomical locations, such as the aorta or for run-offs into lower extremities. Selective catheters are typically used to gain access to more specific vasculature within the body to deliver smaller amounts of contrast. 
•Mariner Hydrophilic Catheters also feature a hydrophilic coating on the distal 20cm of the catheter that reduces friction during catheter advancement in the vasculature and allows for smooth navigation, as well as, optimum handling and control by the physician. 
•Accu-Vu Sizing Catheters are our line of flush catheters that also feature highly visible radiopaque marker bands, which are heat embedded, along the catheter shaft, providing a smooth transition across the catheter shaft to ensure the marker bands will not separate from the shaft. These radiopaque marker bands come in different patterns along the shaft and allow physicians, under fluoroscopy, to take measurements in different anatomical locations for the placement of stents, IVC filters or other devices. The tight tolerances and consistent placement across the entire sizing pattern, within +/-1mm of accuracy, provide a highly accurate measurement to the physician. 
5

AngioDynamics offers a line of diagnostic and interventional guidewires which are designed to aid in delivering diagnostic and/or therapeutic devices to the desired location. 
•The ADx Peripheral Vascular Guidewire line is AngioDynamics diagnostic line of guidewires that is available in a multitude of fixed core wire configurations, including J-Tip and Bentson, in various lengths and outer diameters (OD). By utilizing a proprietary pre-coat process for the Polytetrafluoroethylene (PTFE) and upholding tight specifications, our ADx Guidewires offer high quality and performance for physicians. 
•The NiT-Vu High Performance Micro Guidewires are our highly kink resistant nitinol shaft interventional wires that feature a highly visible radiopaque tungsten tip and lubricious coating. The NiT-Vu wires are designed to reduce friction during wire advancement and also provides torque control, flexibility and kink resistance. 
Drainage Products
To aid physicians in percutaneous drainage procedures, AngioDynamics offers the Total Abscession Drainage Catheters. The Total Abscession Drainage Catheter is available in Multipurpose/General and Biliary configurations, and also offers a Nephrostomy option. The portfolio offers options with a radiopaque marker band at the distal tip to aid in placement.
•The Total Abscession Drainage Catheter line offers a soft, kink resistant shaft that features the lubricious Blue Silk Finish for easier insertion and pushability, while providing the optimal patient comfort. The unique Vault Locking Mechanism securely fixes the pigtail and prevents tampering or accidental removal. 
Micropuncture Kits
AngioDynamics offers physicians two micropuncture kit lines that are designed to start each procedure with ease and efficiency: Mini Stick MAX Coaxial Microintroducer Kits and Micro-Introducer Kits. Each kit features a coaxial design with a 4F or 5F sheath introducer and stiff or standard dilator, along with a 21G needle and various 0.018” access wire configurations. 
•Mini Stick MAX Coaxial Introducer kits contain a unique containment clip that keeps all the unique components of the kit together and organized. The kit options include our AngioDynamics proprietary coaxial introducer with smooth transition at the tip, translucent 21G needle with bevel indicator and 0.018” access wire available in three different wire material configurations. 
•The Micro-Introducer Kits offer a variety of configurations that aid in simplifying set up and gaining vascular access.
Ports 
Ports are implantable devices utilized for the central venous administration of a variety of medical therapies and for blood sampling and diagnostic purposes. Central venous access facilitates a more systemic delivery of treatment agents, while mitigating certain harsh side effects of certain treatment protocols and eliminating the need for repeated access to peripheral veins. Depending upon needle gauge size and the port size, a port can be utilized for up to approximately 2,000 accesses once implanted in the body. Our ports are used primarily in systemic or regional short- and long-term cancer treatment protocols that require frequent infusions of highly concentrated or toxic medications (such as chemotherapy agents, antibiotics or analgesics) and frequent blood samplings. Our port products and accessories include:
•SmartPort, SmartPort+, SmartPort Plastic: The SmartPort power-injectable port with Vortex technology offers the ability for a clinician to access a vein for both the delivery of medications or fluids and for administering power-injected contrast to perform a CT scan. The ability to access a port for power-injected contrast studies eliminates the need for additional needle sticks in the patient’s arm and wrist veins. Once implanted, repeated access to the bloodstream can be accomplished with greater ease and less discomfort. Our SmartPort port line is available in standard, mini and low-profile to accommodate more patient anatomies. The SmartPort+ port line combines Vortex technology with BioFlo catheters. In addition to the three titanium port body sizes, there is a plastic port body.
•BioFlo Port: Our BioFlo Port was the first port available featuring a catheter with Endexo Technology. Advanced features of the BioFlo Port include multiple profile and catheter options, a large septum area for ease of access, PASV and non-PASV valve technology and the ability to administer contrast through a CT injection for purposes of imaging. The BioFlo port family is available in single or dual lumen configurations.
•Xcela Plus: The Xcela Plus Port product family is Power-Injectable and part of a complete portfolio of vascular access products, and is fully compatible with the LifeGuard Safety Infusion product family. It has easily identifiable critical information radiopaque “CT” lettering which helps to confirm if port is power-injectable or flipped. The Xcela Plus port family is available in single lumen standard size in either a non-valved or valved configuration.
6

Port Technologies
•BioFlo Endexo: AngioDynamics offers the BioFlo catheter, the only catheter on the market with Endexo Technology, a material more resistant to thrombus accumulation, in vitro (based on platelet count). Endexo Technology is a permanent and non-eluting polymer that is “blended” into the polyurethane from which the catheter is made. It is present throughout the catheter, including the extraluminal, intraluminal and cut catheter surface of the tip. Endexo Technology remains present for the life of the catheter. The BioFlo catheter’s long-term durability and efficacy is intended to provide clinicians a high degree of safety and confidence in providing better patient care and improved patient outcomes.
•Vortex: Our Vortex port technology line of ports features a clear-flow port technology that, we believe, revolutionized port design. With its rounded chamber, the Vortex port is designed to have no sludge-harboring corners or dead spaces. This product line consists of titanium, plastic and dual-lumen offerings.
•PASV Valve Technology: The PASV Valve Technology is designed to automatically resist backflow and reduce blood reflux that could lead to catheter-related complications.
Venous Insufficiency
VenaCure EVLT laser system 
Our VenaCure EVLT system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Superficial venous disease is a malfunction of one or more valves in the leg veins whereby blood refluxes or does not return to the heart, thereby pooling in the legs and leading to symptoms such as pain, swelling and ulcerations. The VenaCure EVLT system uses laser energy to stop the reflux by ablating (collapsing and destroying) the affected vein. Blood is then re-routed to other healthy veins.

The procedure is minimally invasive and generally takes less than an hour, typically allowing the patient to quickly return to normal activities. 
The VenaCure EVLT system is sold as a system that includes diode laser hardware and procedure kits which include disposable laser fiber components, an access sheath, access wires and needles. Our VenaCure EVLT 1470 nanometer wavelength laser allows physicians to more efficiently heat the vein wall using lower power settings thereby reducing the risk of collateral damage. The NeverTouch tip fiber eliminates laser tip contact with the vein wall, which in turn minimizes perforations of the vein wall that typically result in less pain and bruising as compared to traditional bare-tip fibers. The NeverTouch tip also maximizes ultrasonic visibility, making it easier for physicians to use. Procedure kits are available in a variety of lengths and configurations to accommodate varied patient anatomies.
NeverTouch and NeverTouch Direct gold-tip laser fibers, is an integral part of AngioDynamics’ advanced varicose vein treatment and establishes a new standard for patient comfort, visibility and ease of use. The innovation behind the NeverTouch tip is a glass weld at the distal tip